ArticlePloS one2025
Enhancing glioma immunohistochemical image classification through color deconvolution-aware prior guidance.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioma diagnosis and prognosis heavily rely on immunohistochemistry (IHC), particularly CD34-stained images which highlight tumor vascular endothelial cells. However, traditional image analysis methods struggle with complex staining patterns and subtle morphological variations across glioma subtypes. In this study, we propose a novel Prior-Guided Enhancement Network (PGE-Net) that integrates domain-specific prior knowledge through color deconvolution to enhance feature representation of CD34-positive regions. Unlike existing approaches that treat all pixels equally, our model leverages color abnormality maps to emphasize diagnostically relevant staining patterns, thereby improving both interpretability and classification performance. Experimental evaluation on a curated glioma CD34 dataset demonstrates that PGE-Net achieves notable improvements over ResNet18 baselines, with Precision, Recall, and F1-score increased by 9.17%, 9.35%, and 12.35%, respectively. These results underscore the model's potential for facilitating more accurate and interpretable IHC image analysis in clinical practice, ultimately supporting more personalized and efficient glioma treatment planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.